Bankur Mustafa Nissar, Keeling Archie, Adil Shah Khoodoruth Mohamed, Avenoso Daniele
Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
Neurosciences Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
Hematol Rep. 2022 Jun 23;14(3):213-221. doi: 10.3390/hematolrep14030029.
Herein, we present a case of cytomegalovirus (CMV) colitis that occurred after two cycles of azacitidine and venetoclax in a 64-year-old woman affected with acute myeloid leukaemia (AML) secondary to a previous diagnosis of a hypoplastic myelodysplastic syndrome (hypo-MDS). This patient never had detectable CMV viraemia, and there was no evidence of immune deficiency that could justify this opportunistic infection. Additionally, this is most likely the first report describing CMV colitis in a patient treated upfront with azacitidine and venetoclax.
在此，我们报告一例64岁患有急性髓系白血病（AML）的女性病例，该患者之前诊断为低增生性骨髓增生异常综合征（hypo-MDS），在接受两周期阿扎胞苷和维奈克拉治疗后发生了巨细胞病毒（CMV）结肠炎。该患者从未检测到CMV病毒血症，也没有证据表明存在免疫缺陷可解释这种机会性感染。此外，这很可能是第一份描述在接受阿扎胞苷和维奈克拉一线治疗的患者中发生CMV结肠炎的报告。
